Meeting
2023 ASCO Annual Meeting
Association of positive ctDNA-based minimal residual disease assays during surveillance and undiagnosed concomitant radiographic recurrences in colorectal cancer (CRC): Results from the MD Anderson INTERCEPT program.
Authors
Arvind Dasari
Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
Arvind Dasari , Alisha Heather Bent , Kristin Alfaro-Munoz , Ryan W Huey , Benny Johnson , Michael Sangmin Lee , Maria Pia Morelli , Van K. Morris II, Michael J. Overman , Christine Megerdichian Parseghian , Kanwal Pratap Singh Raghav , John Shen , Jason Willis , Timothy E. Newhook , Abhineet Uppal , Y. Nancy You , Tsuyoshi Konishi , George J. Chang , Scott Kopetz , Robert A. Wolff
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal Cancer—Colorectal and Anal
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer–Local-Regional Disease
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 3522)
DOI
10.1200/JCO.2023.41.16_suppl.3522
Abstract #
3522
Poster Bd #
222
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Minimal residual disease assessment in colorectal cancer (MiRDA-C).
First Author: Arvind Dasari
Poster
2024 ASCO Gastrointestinal Cancers Symposium
INTERCEPT Program of circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) in colorectal cancer (CRC): Results from a prospective clinical cohort.
First Author: Giulia Maddalena
Poster
2024 ASCO Gastrointestinal Cancers Symposium
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.
First Author: Andrew Jared Pellatt
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Circulating tumor DNA (ctDNA) informs clinical practice in patients with recurrent/metastatic gastroesophageal cancers.
First Author: Rutika Mehta